Sonoma Pharmaceuticals Highlights Growth in Healthcare Sector

Sonoma Pharmaceuticals (SNOA) has announced its growth in the healthcare sector, highlighting its expanded wound care business through partnerships with major distributors like Medline Industries. The company has introduced new applications for its Microcyn technology and maintains a strong regulatory portfolio. Analysts rate SNOA stock as a Hold with a $4.00 price target, while Spark's AI Analyst gives it a Neutral rating. Despite strong revenue growth, challenges in profitability and cash flow management suggest caution for potential investors. Sonoma specializes in stabilized hypochlorous acid products used in various healthcare applications.